Phillis Rutt, NP
Family · Englewood, CONPI 1447564109
Payments from drug & device makers
Across 108 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$349
- AbbVie$300
- GSK$224
- AstraZeneca$180
- Novo Nordisk$170
- Astellas Pharma US Inc$155
- plus $955 from 22 others
What the payments were for
- Food & beverage$2,334100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $349 |
| AbbVie | 9 | $300 |
| GSK | 11 | $224 |
| AstraZeneca | 11 | $180 |
| Novo Nordisk | 8 | $170 |
| Astellas Pharma US Inc | 6 | $155 |
| Exact Sciences | 5 | $109 |
| Lilly USA, LLC | 5 | $104 |
| Johnson & Johnson | 4 | $96 |
| Edwards Lifesciences | 2 | $69 |
| Bayer | 3 | $64 |
| Boehringer Ingelheim | 3 | $59 |
| Abiomed | 2 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Dexcom, Inc. | 2 | $38 |
| Abbott | 2 | $38 |
| Amgen(2 entities) | 2 | $34 |
| Merck | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Lucid Diagnostics Inc. | 1 | $24 |
| Sonex Health, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $16 |
How this compares
$2,334 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $29,971 |
| JardianceEmpagliflozin | 19 | $19,689 |
| MyrbetriqMirabegron | 22 | $18,504 |
| EliquisApixaban | 14 | $12,815 |
| XareltoRivaroxaban | 14 | $9,661 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,171 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,859 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,834 |
| Sumatriptan Succinate | 13 | $2,043 |
| Estradiol | 17 | $1,816 |
| Omeprazole | 92 | $1,719 |
| Gabapentin | 83 | $1,533 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,462 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,446 |
| Atorvastatin Calcium | 173 | $1,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $170 | $29,97124 claims |
| Boehringer IngelheimJardiance | $59 | $19,68919 claims |
| Astellas Pharma US IncMyrbetriq | $155 | $18,50422 claims |
| GSKBreo Ellipta, Anoro Ellipta, Incruse Ellipta | $224 | $16,86434 claims |
| PfizerEliquis | $349 | $12,81514 claims |
| Johnson & JohnsonXarelto | $96 | $9,66114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.
Other family in Englewood
- Taylor CampbellEnglewood$16K
- Meagan MurgelEnglewood$11K
- Jennifer BurkeEnglewood$9K
- Brook KilianEnglewood$8K
- Annette WychgramEnglewood$8K
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.